L-163,491 Explained

L-163,491 is an experimental drug which acts as a partial agonist of angiotensin II receptor type 1, and with lower affinity as an agonist of angiotensin II receptor type 2, mimicking the action of angiotensin II.^[1] Its practical applications to date have been limited to scientific research into the function of the angiotensin receptor system,^[2] but it has been suggested as a potential therapeutic agent for the treatment of inflammation of the lungs associated with certain viral diseases such as COVID-19.^{[3] [4]}

Notes and References

1. De Witt BJ, Garrison EA, Champion HC, Kadowitz PJ . L-163,491 is a partial angiotensin AT(1) receptor agonist in the hindquarters vascular bed of the cat . European Journal of Pharmacology . 404 . 1–2 . 213–9 . September 2000 . 10980281 . 10.1016/s0014-2999(00)00612-9 .
2. Alterman M . Development of selective non-peptide angiotensin II type 2 receptor agonists . Journal of the Renin-Angiotensin-Aldosterone System . 11 . 1 . 57–66 . March 2010 . 19880657 . 10.1177/1470320309347790 . free .
3. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S, Albaiu D . 6 . Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases . ACS Central Science . 2020 . 6 . 3 . 315–331 . 10.1021/acscentsci.0c00272 . 32226821 . 7094090 . free .
4. Wu Y . Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury . Virologica Sinica . 35. 3. 256–258. February 2020 . 32034638 . 10.1007/s12250-020-00205-6 . 7091449 . free .